Cara Therapeutics to Present at May Investor Conferences

Rhea-AI Summary

Cara Therapeutics (Nasdaq: CARA), a biopharmaceutical company focused on treatments for pruritus, announced that CEO Christopher Posner will present at two investor conferences in May 2022. The first event is the BofA Securities 2022 Healthcare Conference on May 10 at 2 p.m. PT / 5 p.m. ET, followed by the H.C. Wainwright Global Investment Conference on May 25 at 2:30 p.m. ET. Webcasts of the presentations will be available on the company's website for 30 days. Cara is known for its FDA-approved KORSUVA™ (difelikefalin) injection for treating pruritus in chronic kidney disease.

STAMFORD, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the following investor conferences in May:

BofA Securities 2022 Healthcare Conference
Tuesday, May 10, 2022, at 2 p.m. PT / 5 p.m. ET

H.C. Wainwright Global Investment Conference
Wednesday, May 25, 2022, at 2:30 p.m. ET

Webcasts of the presentations can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. Archived webcast recordings will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. Phase 2 trials of Oral KORSUVA (difelikefalin) are ongoing in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com

FAQ

What is the schedule for Cara Therapeutics' presentations at investor conferences in May 2022?

Cara Therapeutics will present at the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 2 p.m. PT / 5 p.m. ET, and at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 2:30 p.m. ET.

Where can I access the webcasts of Cara Therapeutics' presentations?

Webcasts of Tara Therapeutics' presentations can be accessed under the 'Events & Presentations' section of their website and will be available for 30 days.

What is KORSUVA by Cara Therapeutics?

KORSUVA™ (difelikefalin) is the first FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.

Is Cara Therapeutics developing any new treatments?

Yes, Cara Therapeutics is developing an oral formulation of difelikefalin and is conducting Phase 3 studies for non-dialysis dependent advanced chronic kidney disease and atopic dermatitis.